Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese

被引:32
|
作者
Takakubo, F
Kuwano, A
Kondo, I
机构
[1] Department of Hygiene, Ehime University, School of Medicine, Onsen-gun
来源
PHARMACOGENETICS | 1996年 / 6卷 / 03期
关键词
(S)-mephenytoin; poor metabolizer; CYP2C19m1 and CYP2C19m2;
D O I
10.1097/00008571-199606000-00011
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
(S)-Mephenytoin is metabolized by CYP2C19. The purpose of this study was to examine availability of phenotyping of poor metabolizers (PMs) of (S)-mephenytoin by polymerase chain reaction(PCR)/restriction enzyme genotyping of CYP2C19 in a Japanese population. We genotyped 217 unrelated healthy Japanese for functionally defective alleles, CYP2C19m1 and CYP2C19m2. The frequencies of the wild type (W-m1) and CYP2C19m1 were 0.726 and 0.274, and the wild type(W-m2) and CYP2C19m2 were 0.892 and 0.108 respectively, Although the observed numbers of three genotypes were very similar to those estimated according to the Hardy-Weinberg equilibrium for each defect, CYP2C19m2 was not detected in m2 homozygotes, and CYP2C19m1 was not detected in m2 homozygotes. Two defects were inherited separately in four families indicating CYP2C19m1 and m2 segregate independently at the same gene locus, Based on these data, we calculated the haplotype frequencies of W-m1-W-m2, CYP2C19m1-W-m2 and W-m1-CYP2C19m2 to be 0.618, 0.274 and 0.108 respectively, frequencies of homozygotes for CYP2C19m1 and CYP2C19m2 and compound heterozygotes associated with the PM phenotype, were calculated to be 7.5, 1.2 and 5.9% respectively, In total, 14.6% of Japanese are estimated to be PMs, No significant difference was observed between the frequencies of PMs calculated from our results and that identified by urinary S/R ratio (18%) (p>0.05, chi 2=0.545, f(d)=1). Our data indicate that Japanese PMs of (S)-mephenytoin could be identified by PCR-based genotyping of CYP2C19.
引用
收藏
页码:265 / 267
页数:3
相关论文
共 50 条
  • [1] Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers
    Lei, He-Ping
    Wang, Guo
    Wang, Lian-Sheng
    Ou-yang, Dong-sheng
    Chen, Hao
    Li, Qing
    Zhang, Wei
    Tan, Zhi-Rong
    Fan, Lan
    He, Yi-Jing
    Zhou, Hong-Hao
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (04) : 726 - 731
  • [2] An S-mephenytoin cysteine conjugate identified in urine of extensive but not of poor metabolizers of S-mephenytoin
    Tyring, G
    Nordin, J
    Bergman, T
    Bertilsson, L
    PHARMACOGENETICS, 1997, 7 (05): : 355 - 360
  • [3] Functional characterization of two novel CYP2C19 variants (CYP2C19*18 and CYP2C19*19) found in a Japanese population
    Hanioka, N.
    Tsuneto, Y.
    Saito, Y.
    Sumada, T.
    Maekawa, K.
    Saito, K.
    Sawada, J.
    Narimatsu, S.
    XENOBIOTICA, 2007, 37 (04) : 342 - 355
  • [4] A MULTIFAMILY STUDY ON THE RELATIONSHIP BETWEEN CYP2C19 GENOTYPE AND S-MEPHENYTOIN OXIDATION PHENOTYPE
    BROSEN, K
    DEMORAIS, SMF
    MEYER, UA
    GOLDSTEIN, JA
    PHARMACOGENETICS, 1995, 5 (05): : 312 - 317
  • [5] CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
    He, N
    Yan, FX
    Huang, SL
    Wang, W
    Xiao, ZS
    Liu, ZQ
    Zhou, HH
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 58 (01) : 15 - 18
  • [6] Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity
    Klaassen, Tobias
    Jetter, Alexander
    Tomalik-Scharte, Dorota
    Kasel, Dirk
    Kirchheiner, Julia
    Jaehde, Ulrich
    Fuhr, Uwe
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) : 387 - 398
  • [7] Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity
    Tobias Klaassen
    Alexander Jetter
    Dorota Tomalik-Scharte
    Dirk Kasel
    Julia Kirchheiner
    Ulrich Jaehde
    Uwe Fuhr
    European Journal of Clinical Pharmacology, 2008, 64 : 387 - 398
  • [8] Characterization of CYP2C19 and CYP2C9 from human liver:: Respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations
    Lasker, JM
    Wester, MR
    Aramsombatdee, E
    Raucy, JL
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1998, 353 (01) : 16 - 28
  • [9] Genetic polymorphism of CYP2C19 in a Jordanian population: influence of allele frequencies of CYP2C19*1 and CYP2C19*2 on the pharmacokinetic profile of lansoprazole
    Zalloum, Imad
    Hakooz, Nancy
    Arafat, Tawfiq
    MOLECULAR BIOLOGY REPORTS, 2012, 39 (04) : 4195 - 4200
  • [10] A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine
    Jornil, J.
    Nielsen, T. S.
    Rosendal, I.
    Ahlner, J.
    Zackrisson, A. L.
    Boel, L. W. T.
    Brock, B.
    FORENSIC SCIENCE INTERNATIONAL, 2013, 226 (1-3) : E26 - E31